B-cell Acute Lymphoblastic Leukemia: Clinical Trials

43 trials for B-cell Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 recruiting, 7 withdrawn, 6 active not recruiting, 6 unknown. 43 Phase 2, 21 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 243Recruiting 16, Withdrawn 7, Active not recruiting 6, Unknown 6, Completed 5, Not yet recruiting 2, Terminated 1
Phase 121Recruiting 8, Unknown 4, Withdrawn 3, Active not recruiting 2, Completed 2, Not yet recruiting 2
Phase 31Recruiting 1

Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 43 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult
Phase 1 / Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center262026-12-012026-11-09
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32026-01-302026-08-18
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingLiping Dou202026-01-012026-06-15
Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingLiping Dou302026-01-012026-06-25
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2WithdrawnJuventas Cell Therapy Ltd.2025-06-302025-08-08
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingVironexis Biotherapeutics Inc.322025-05-302026-10-26
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
YK012 - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingExcyte Biopharma Ltd462024-09-252026-02-06
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Zilovertamab vedotin - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC902024-08-162026-10-30
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Inaticabtagene autoleucel - B-cell Acute Lymphoblastic Leukemia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China202024-08-012024-11-05
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Decitabine, venetoclax and blinatumomab - B-cell Acute Lymphoblastic Leukemia
Phase 2RecruitingThe First Affiliated Hospital of Soochow University302024-04-252024-11-19
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
single dose of CNCT19 - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingJuventas Cell Therapy Ltd.472023-02-072025-08-12
Co-administration of CART22-65s and huCART19 for B-ALL
Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) - B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Phase 1 / Phase 2RecruitingStephan Grupp MD PhD932023-01-252026-03-27
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
UCAR-T Cells - B-cell Acute Lymphoblastic Leukemia, B-ALL
Phase 1 / Phase 2Unknown920th Hospital of Joint Logistics Support Force of People's Liberation Army of China302022-12-052022-12-08
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
CD19 CAR T-Cell(CAT19T2) - B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified
Phase 1 / Phase 2WithdrawnZhujiang Hospital2022-12-012024-03-18
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
U-CAR-T Cells (LstCAR019) - B-cell Acute Lymphoblastic Leukemia, B-ALL
Phase 1 / Phase 2WithdrawnKunming Hope of Health Hospital2022-10-012022-11-30
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Tisagenlecleucel - B-cell Acute Lymphoblastic Leukemia
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center302022-07-122026-02-04
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Anti-CD19 CAR T-cells - Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children
Phase 2RecruitingKK Women's and Children's Hospital402022-03-152023-03-09
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
IDEAL2 Intervention - B-cell Acute Lymphoblastic Leukemia, Obesity
Phase 2RecruitingEtan Orgel2402022-03-122026-08-19

Showing 20 of 43. Sign in to see all of them.

Narrower conditions

Burkitt Lymphoma (43)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)  ·  Recurrence (6)  ·  Leukemia (4)  ·  Lymphoma (4)  ·  Lymphoma, B-Cell (4)  ·  Neoplasm, Residual (4)  ·  Lymphoma, Large B-Cell, Diffuse (3)  ·  Leukemia, B-Cell (2)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Renal Cell (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Glioma (1)  ·  Leukemia, Biphenotypic, Acute (1)

Broader conditions

DNA Virus Infections (43)  ·  Epstein-Barr Virus Infections (43)  ·  Hemic and Lymphatic Diseases (43)  ·  Herpesviridae Infections (43)  ·  Immune System Diseases (43)  ·  Immunoproliferative Disorders (43)  ·  Infections (43)  ·  Neoplasms by Histologic Type (43)  ·  Tumor Virus Infections (43)  ·  Virus Diseases (43)  ·  Lymphatic Diseases (42)  ·  Lymphoma, Non-Hodgkin (42)  ·  Lymphoproliferative Disorders (42)  ·  Neoplasms (42)  ·  Lymphoma (39)

Interventions

blinatumomab (10)  ·  tisagenlecleucel (6)  ·  Dexamethasone (3)  ·  Immunotherapy, Adoptive (3)  ·  Cyclophosphamide (2)  ·  tocilizumab (2)  ·  Acetaminophen (1)  ·  Alemtuzumab (1)  ·  Azacitidine (1)  ·  Cytarabine (1)  ·  Decitabine (1)  ·  Diphenhydramine (1)  ·  Etoposide (1)  ·  Injections (1)  ·  Inotuzumab Ozogamicin (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  The First Affiliated Hospital of Soochow University (4)  ·  Juventas Cell Therapy Ltd. (2)  ·  Liping Dou (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Merck Sharp & Dohme LLC (2)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Amgen Research (Munich) GmbH (1)  ·  Autolus Limited (1)  ·  BeOne Medicines (1)  ·  Beijing Tongren Hospital (1)  ·  BioCryst Pharmaceuticals (1)  ·  Cellectis S.A. (1)  ·  Dorothy Sipkins, MD, PhD (1)

Countries

United States (17)  ·  China (16)  ·  France (6)  ·  Italy (5)  ·  Spain (5)  ·  Belgium (4)  ·  Canada (4)  ·  Germany (4)  ·  Netherlands (4)  ·  United Kingdom (4)  ·  Denmark (3)  ·  Sweden (3)  ·  Australia (2)  ·  Austria (2)  ·  Greece (2)

Top investigators

Abdel-Azim Hisham, MD (1)  ·  Aloysius Ho, MD (1)  ·  Christian Schmidt, MD (1)  ·  Dorothy Sipkins, MD (1)  ·  Elias Jabbour, MD (1)  ·  Jae Park, MD (1)  ·  Jianxiang Wang M.D. (1)  ·  Jie Jin, MD (1)  ·  Kevin Curran, MD (1)  ·  Li Li, MD (1)  ·  Lihua Yang (1)  ·  Marion Subklewe, MD (1)  ·  Michael Burke, MD (1)

Results publications

PMID 41671463, PMID 33496754, PMID 34353848, PMID 34432863, PMID 35422096, PMID 27209293, PMID 29358182, PMID 29385370, PMID 30254079, PMID 31606419, PMID 32589970, PMID 32619115, PMID 33843815, PMID 34893603, PMID 36399695, PMID 36821767, PMID 38135369, PMID 41199560, PMID 42525896

NIH funding

2017 (2), 2023 (2), 2015 (1), 2016 (1), 2025 (1)